Gilead Sciences, Inc.

Brian P Bestvater

Chandrasekar Venkataramani

Peiyuan Wang

Barton W Phillips

Zhimin Du

Julie Farand

Kin Shing Yang

Doris T Tang

Anna Zagorska

Gregory Notte

Joshua A Kaplan

The present disclosure relates generally to compounds that bind to Lysophosphatidic Acid Receptor 1 (LPAR1) and act as antagonists of LPAR1. The disclosure further relates to the use of the compounds for the preparation of a medicament for the treatment of diseases and/or conditions through binding of LPAR1, including fibrosis and liver diseases such as non-alcoholic steatohepatitis (NASH), interstitial lung disease (ILD), or chronic kidney disease (CKD).

LPA receptor antagonists and uses thereof

The present disclosure relates generally to compounds that bind to Lysophosphatidic Acid Receptor 1 (LPAR1) and act as antagonists of LPAR1. The disclosure further relates to the use of the compounds for the preparation of a medicament for the treatment of diseases and/or conditions through binding of LPAR1, including fibrosis and liver diseases such as non-alcoholic steatohepatitis (NASH).

Triazole carbamate pyridyl sulfonamides as LPA receptor antagonists and uses thereof

Growing community of inventors

San Mateo, CA, United States of America

Brian P Bestvater